Drug profile

The FDA adverse-event record for Genta/Posacon/Mometa Eardrops

139 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Genta/Posacon/Mometa Eardrops. See the species affected, top reactions, and outcomes below.

139
adverse-event reports
0.7%
death-coded share
Dog
most-reported species
37
Lack of efficacy - NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
139
Total Reports
1
Deaths Reported
0.7%
Death Rate

Active Ingredients

Genta/Posacon/Mometa Eardrops

Administration Routes

Auricular (Otic)TopicalUnknownOral

Species Affected

Dog 136
Cat 2
Unknown 1

Most Affected Breeds

Crossbred Canine/dog 44
Retriever - Labrador 15
Bulldog - French 10
Unknown 5
Retriever - Golden 5
Shepherd Dog - German 4
Pug 3
Pit Bull 3
Bichon Frise 3
Dog (unknown) 3

Most Reported Reactions

Lack of efficacy - NOS 37
Lack of efficacy (bacteria) - NOS 35
Lack of efficacy (fungi) - NOS 28
Deafness 12
Head shake - ear disorder 9
Ear canal inflammation 8
Lethargy (see also Central nervous system depression in Neurological) 8
Head tilt - ear disorder 8
Medication error NOS 7
Behavioural disorder NOS 6
Ear discharge 6
Ear pain 6

Outcome Breakdown

Ongoing
101 (73.2%)
Outcome Unknown
17 (12.3%)
Recovered with Sequela
13 (9.4%)
Recovered/Normal
6 (4.3%)
Died
1 (0.7%)

Genta/Posacon/Mometa Eardrops Adverse Event Insights

139 reports name Genta/Posacon/Mometa Eardrops; 1 recorded a death outcome (0.7% of reported events, not a population-level mortality rate). Active ingredient: Genta/Posacon/Mometa Eardrops. Administration routes: Auricular (Otic), Topical, Unknown, Oral.

By species: Dog (136 reports), Cat (2 reports), Unknown (1 reports). By breed: Crossbred Canine/dog (44), Retriever - Labrador (15), Bulldog - French (10).

Leading clinical signs: Lack of efficacy - NOS (37), Lack of efficacy (bacteria) - NOS (35), Lack of efficacy (fungi) - NOS (28), Deafness (12). Outcome, 138 coded reports: Ongoing leads at 73.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.